James P. Allison, a famous American immunologist, is currently professor and department director of immunology at M. D. Anderson Cancer Center of the University of Texas, the executive director of the immunotherapy platform, and the director of the Scientific Advisory Committee of the Cancer Research Institute (CRI). [1-4]

Allison is mainly known for its research on T-cell antigen receptor complex, costimulatory molecule receptor and other molecules that stimulate T cells. In particular, he focused on searching for signals that guide the differentiation of naive T cells, and those that determine whether the participation of antigen receptors triggers the activation of T cell function. These studies may contribute to the designation of new strategies to combat autoimmune diseases and the immunotherapy of cancer.

On September 21, 2016, he was selected into the list of 2016 Citation Laureate Awards [5]. In December 2016, it was awarded the first "Fudan Zhongzhi Science Award". [6]

On October 1, 2018, the 2018 Nobel Prize in Physiology or Medicine was announced, and James Allison and Ben Shuyou jointly won the prize, in recognition of their "contributions to the discovery of negative immunomodulation therapy for cancer". [7]

詹姆斯·艾利森（James P. Allison），美国著名的免疫学家，现任美国德克萨斯大学安德森（M. D. Anderson）癌症中心免疫学教授和系主任、免疫治疗平台执行主任，同时担任美国癌症研究所（Cancer Research Institute，CRI）科学顾问委员会的主任。 [1-4]    

艾利森主要以对T细胞抗原受体复合体、协同刺激分子受体以及刺激T细胞的其他分子的研究而知名。他尤其把精力放在搜寻那些引导区分幼稚T细胞的信号，以及那些决定抗原受体的参与是否引发T细胞功能的激活的信号上面。这些研究可能对指定攻克自身免疫性疾病的新策略，以及癌症的免疫治疗有促进的作用。

2016年9月21日，入选2016年引文桂冠奖名单 [5]  。2016年12月，获颁首届“复旦-中植科学奖”。 [6] 

2018年10月1日，2018年诺贝尔生理学或医学奖揭晓，詹姆斯·艾利森和本庶佑共同获奖，以表彰他们“发现负性免疫调节治疗癌症的疗法方面的贡献”。 [7] 

https://baike.baidu.com/item/%E8%A9%B9%E5%A7%86%E6%96%AF%C2%B7%E8%89%BE%E5%88%A9%E6%A3%AE/15826850?fromModule=lemma_inlink

https://pubmed.ncbi.nlm.nih.gov/22071753/

summary-AllisonJP-set.txt

http://www.pubmedplus.cn/P/SearchQuickResult?wd=dbd7764c-6a90-47dc-aa42-fced943ebdef

• 年份

• 记录数占%

• 期刊

• 记录数占%

• 国家

• 记录数占%

• 中国城市

• 境外城市

• 记录数占%

• 主题词

• 记录数占%

No abstract available

Similar articles

• Innate immunity's path to the Nobel Prize 2011 and beyond.

  Wagner H.Eur J Immunol. 2012 May;42(5):1089-92. doi: 10.1002/eji.201242404.PMID: 22539282

• The 2011 Nobel Prize--honoring the memory of Dr. Ralph Steinman.

  Bona C, Bot A.Int Rev Immunol. 2011 Oct-Dec;30(5-6):233-4. doi: 10.3109/08830185.2011.630972.PMID: 22053967 No abstract available.

• [The Nobel Prize in Physiology and Medicine 2011].

  Carrillo-Maravilla E, Llorente L.Rev Invest Clin. 2012 Jan-Feb;64(1):5-8.PMID: 22690523 Spanish. No abstract available.

• The history of Toll-like receptors - redefining innate immunity.

  O'Neill LA, Golenbock D, Bowie AG.Nat Rev Immunol. 2013 Jun;13(6):453-60. doi: 10.1038/nri3446. Epub 2013 May 17.PMID: 23681101 Review.

• Toll-like receptor regulation of effector T lymphocyte function.

  Reynolds JM, Dong C.Trends Immunol. 2013 Oct;34(10):511-9. doi: 10.1016/j.it.2013.06.003. Epub 2013 Jul 22.PMID: 23886621 Review.

See all similar articles

Cited by

• Living in a Hostile World: Inflammation, New Drug Development, and Coronavirus.

  Dobson GP, Biros E, Letson HL, Morris JL.Front Immunol. 2021 Jan 22;11:610131. doi: 10.3389/fimmu.2020.610131. eCollection 2020.PMID: 33552070 Free PMC article. Review.

• Application of built-in adjuvants for epitope-based vaccines.

  Lei Y, Zhao F, Shao J, Li Y, Li S, Chang H, Zhang Y.PeerJ. 2019 Jan 14;6:e6185. doi: 10.7717/peerj.6185. eCollection 2019.PMID: 30656066 Free PMC article.

References

1. 
   

1. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13 - PubMed

2. 
   

1. Nature. 1997 Jul 24;388(6640):394-7 - PubMed

Publication types

• Historical Article

• Letter

MeSH terms

• Adaptive Immunity / immunology

• History, 20th Century

• Immunity, Innate / immunology

• Models, Immunological

• Nobel Prize*

• Toll-Like Receptors / history*

• Toll-Like Receptors / immunology

Substances

• Toll-Like Receptors

LinkOut - more resources

• Full Text Sources

• Nature Publishing Group

• Ovid Technologies, Inc.